NIH R01 · 2025
Improving Equitable Access to Penicillin Allergy De-Labeling
Project Summary The global public health strategy to decrease mortality from antimicrobial resistant (AMR) infections encourages removal of inaccurate penicillin (PCN) allergy labels, termed “de-labeling.” PCN allergy de-labeling is recommended as ~10% of all people report a PCN allergy, but only 5% of those (i.e., <1%) have a true PCN allergy confirmed after formal testing. Prescription of alternative antibiotics in individuals with PCN allergy labels results in inferior clinical outcomes, increased adverse events including Clostridioides difficile infection, increased methicillin-resistant Staphylococcus aureus, and increased health care costs. PCN allergy de- labeling is an…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.